VanEck Pharmaceutical ETF
PPH
44 hedge funds and large institutions have $57.7M invested in VanEck Pharmaceutical ETF in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 7 closing their positions.
42% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $1.65M
10% less funds holding
Funds holding: 49 → 44 (-5)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
69.87% less ownership
Funds ownership: 102.62% → 32.75% (-70%)
72% less capital invested
Capital invested by funds: $206M → $57.7M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.51M |
| 2 |
DI
DFPG Investments
Sandy,
Utah
|
+$619K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$92.4K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$84.2K |
| 5 |
WI
Wintrust Investments
Chicago,
Illinois
|
+$73.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$72.7M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$55.7M |
| 3 |
Goldman Sachs
New York
|
-$4.89M |
| 4 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$4.45M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$893K |
PPH Hedge Fund Activity: Q1 2020 in Review
44 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2020, worth a combined $57.7M — down 72% from $206M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PPH and 4 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was Bank of America, adding an estimated $4.51M. The largest seller was Credit Suisse, exiting entirely with an estimated $72.7M sold.
- 44 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2020, down from 49 in Q4 2019.
- Funds reported $57.7M of VanEck Pharmaceutical ETF stock for Q1 2020, down 72% quarter-over-quarter.
- 4 funds opened new VanEck Pharmaceutical ETF positions in Q1 2020 and 7 closed out, a net change of -3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2020 was Bank of America, an estimated $4.51M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2020 was Credit Suisse, an estimated $72.7M sold.
Based on aggregated 13F filings for Q1 2020.